At a $326M market cap, AVBH screens optically cheap with a 7.8 forward P/E and a modest 1.2 price-to-book, but that valuation is not a gift—it is a distress signal. An Altman Z-Score of 0.1 places the company deep in the financial danger zone, while a negative 7.00% operating margin and expected EPS next year of -$2.25 undermine the credibility of forward earnings assumptions. The market is pricing in survival, not growth, and the combination of a low multiple with extreme balance sheet stress suggests this is a balance-sheet recovery speculation rather than a classic GARP mispricing.